The superiority of ripretinib to sunitinib in patients with secondary mutations in exons 17/18 of the KIT gene justified the conduct of the INSIGHT trial, a randomised, open-label, Phase III study of ripretinib versus sunitinib in patients with advanced GIST previously treated with imatinib with co-occurring KIT mutations in exon 11 and exon 17 and/or 18 confirmed by ctDNA analysis [38]. The gene discussed is KIT; the disease is gastrointestinal stromal tumor.